Plasmablastic lymphoma is a rare and aggressive form of cancer affecting white blood cells that often strikes people with weakened immune systems. Despite being uncommon, understanding the available treatment options—from standard chemotherapy to innovative therapies in clinical trials—can help patients and families navigate this challenging diagnosis with greater knowledge and hope.

Fighting an Aggressive Disease: What Treatment Aims to Achieve

When someone receives a diagnosis of plasmablastic lymphoma, the path forward focuses on controlling a fast-moving disease. This rare cancer develops when certain immune cells called plasmablasts—cells that normally sit between early immune cells and mature infection-fighting cells—become cancerous and multiply out of control. The primary goals of treatment include slowing the cancer’s progression, managing symptoms that affect daily life, and whenever possible, achieving complete remission where no cancer cells can be detected in the body.^[1]

Treatment decisions depend heavily on several factors unique to each person. The stage of disease at diagnosis matters significantly—whether the cancer appears in one location or has spread throughout the body. Patient characteristics including overall health, immune system status, and whether someone has HIV or has received an organ transplant all influence which therapies doctors recommend. Age and physical fitness also play important roles, as some treatments require the body to withstand intensive chemotherapy regimens.^[4]

Medical societies have established standard treatment approaches based on research and clinical experience with this rare lymphoma. However, because plasmablastic lymphoma affects relatively few people, ongoing research through clinical trials continues to explore new therapeutic strategies. These trials investigate whether innovative drugs and treatment combinations might improve outcomes for patients facing this aggressive disease. The rarity of plasmablastic lymphoma means that determining the absolute best treatment approach remains challenging, making each new research finding valuable for future patients.^[1]

The aggressive nature of plasmablastic lymphoma means that treatment typically begins soon after diagnosis. Unlike some cancers where doctors might recommend watchful waiting, this lymphoma grows rapidly and can spread quickly to multiple parts of the body. Early intervention offers the best chance for controlling the disease, though the cancer’s tendency to resist standard treatments and return after initial therapy creates ongoing challenges for patients and their medical teams.^[8]

Standard Chemotherapy: The Foundation of Treatment

Chemotherapy remains the cornerstone of treating plasmablastic lymphoma, representing the main weapon doctors use against this aggressive cancer. The most commonly used regimen is called CHOP, which stands for a combination of four drugs: cyclophosphamide, doxorubicin (also known by its trade name Adriamycin, which gives the “H” in CHOP), vincristine (Oncovin), and prednisone. These medications work together to kill rapidly dividing cancer cells throughout the body.^[10]

Each drug in the CHOP regimen attacks cancer cells in different ways. Cyclophosphamide damages the genetic material inside cancer cells, preventing them from dividing. Doxorubicin interferes with enzymes that cancer cells need to copy their DNA. Vincristine stops cancer cells from separating into two new cells. Prednisone, a steroid, helps kill lymphoma cells and reduces inflammation while also making the other drugs more effective. Patients typically receive CHOP chemotherapy in cycles, with treatment given every two to three weeks, allowing the body time to recover between doses.^[1]

For patients who can physically tolerate more intensive treatment, doctors may recommend a regimen called DA-EPOCH. This stands for dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin. The dose-adjusted nature means that doctors carefully calibrate the amount of each drug based on how a patient’s blood counts respond. DA-EPOCH delivers chemotherapy continuously over several days through an infusion pump, which some research suggests may be more effective than standard CHOP for aggressive lymphomas like plasmablastic lymphoma.^[8]

The duration of chemotherapy treatment varies based on how well the cancer responds and the specific regimen used. Most patients receive between four to six cycles of chemotherapy, with each cycle spanning two to three weeks. Doctors use imaging tests and sometimes biopsies between cycles to assess whether the cancer is shrinking. If the lymphoma responds well and disappears completely, this is called achieving complete remission—a critical milestone that affects long-term survival.^[8]

Side effects from chemotherapy can significantly impact quality of life during treatment. Common effects include severe nausea and vomiting, though modern anti-nausea medications have greatly improved control of these symptoms. Hair loss occurs with most regimens, typically beginning two to three weeks after treatment starts. The chemotherapy also damages healthy blood cells, leading to low white blood cell counts that increase infection risk, low red blood cell counts causing fatigue, and low platelet counts that can result in easy bruising or bleeding.^[1]

Many patients experience extreme fatigue during chemotherapy that persists even with adequate rest. Mouth sores can develop, making eating painful and increasing infection risk. Some chemotherapy drugs, particularly vincristine, can damage nerves, causing numbness, tingling, or pain in hands and feet—a condition called peripheral neuropathy. Doxorubicin can affect heart function, so doctors monitor heart health closely during treatment. The intensity and duration of side effects vary considerably between individuals, with some people managing relatively well while others find the treatment extremely challenging.^[4]

For patients who achieve complete remission after initial chemotherapy, doctors may recommend consolidation with autologous stem cell transplantation. This intensive procedure involves collecting a patient’s own stem cells, giving very high doses of chemotherapy to eliminate any remaining cancer cells, then returning the collected stem cells to help the bone marrow recover. This approach aims to reduce the risk of cancer returning, though the procedure itself carries significant risks and requires weeks to months of recovery.^[8]

One challenge specific to plasmablastic lymphoma is that the cancer cells typically do not express a protein called CD20 on their surface. This matters because rituximab, a widely used antibody drug that targets CD20 and has revolutionized treatment for many other lymphomas, generally does not work against plasmablastic lymphoma. The absence of this effective weapon from the treatment arsenal partly explains why outcomes for plasmablastic lymphoma remain poorer than for other types of large B-cell lymphomas.^[8]

Radiation Therapy: Targeted Treatment for Localized Disease

Radiation therapy uses high-energy beams to kill cancer cells in specific areas of the body. For plasmablastic lymphoma, radiation serves multiple purposes depending on the situation. Doctors may use radiation after chemotherapy to treat areas where large masses of cancer existed, helping ensure that any remaining cancer cells in those locations are eliminated. Radiation can also provide effective symptom relief when cancer causes pain, bleeding, or other problems in a particular location.^[8]

Patients with limited-stage disease—meaning the cancer appears in just one area or a few nearby areas—may receive radiation as part of their initial treatment plan. After completing chemotherapy, focused radiation to the affected area can improve the chances of keeping the cancer from returning. This combined approach of chemotherapy followed by radiation has helped some patients, particularly children and those with early-stage disease, achieve long-term survival.^[8]

The radiation treatment process typically involves daily sessions over several weeks, with each session lasting just a few minutes. The radiation therapist carefully positions the patient to ensure the beams target only the intended area while minimizing exposure to surrounding healthy tissue. Side effects depend on which body part receives radiation. Common effects include skin irritation similar to sunburn in the treatment area, fatigue that builds over the course of treatment, and specific symptoms related to the treated location—such as mouth soreness if the head and neck receive radiation, or digestive upset if the abdomen is treated.^[8]

Surgery: A Limited Role

Surgery plays a limited role in treating plasmablastic lymphoma compared to its importance in many solid tumors. Because this lymphoma typically spreads through the lymphatic system and bloodstream rather than growing as a single solid mass, removing the cancer surgically is rarely curative. However, surgery may be necessary in specific situations. If a tumor causes obstruction of the digestive tract, creating a surgical bypass or removing the obstructing mass might be required to restore normal function.^[10]

The main surgical procedure most patients undergo is biopsy to diagnose the disease. Doctors remove a sample of suspicious tissue, which pathologists then examine under a microscope and test with special stains and genetic analyses to confirm plasmablastic lymphoma. In rare cases where the disease appears truly confined to one small area, surgical removal combined with chemotherapy and radiation might be considered, though this scenario is uncommon given the aggressive nature of the disease.^[1]

Breaking New Ground: Innovative Therapies in Clinical Trials

Given the poor outcomes with standard chemotherapy alone, researchers are actively investigating new treatment approaches through clinical trials. These studies test whether innovative drugs and strategies can improve survival and quality of life for patients with plasmablastic lymphoma. Understanding the phases of clinical trials helps patients interpret what these studies mean. Phase I trials primarily assess safety, determining appropriate doses of new drugs. Phase II trials evaluate whether a treatment shows promise in fighting the cancer. Phase III trials compare new treatments against current standard approaches to determine if the innovation truly represents an improvement.^[4]

One promising avenue involves drugs originally developed for multiple myeloma, a different cancer that shares some characteristics with plasmablastic lymphoma. Both diseases involve cells in the plasma cell lineage, leading researchers to wonder if myeloma treatments might help against plasmablastic lymphoma. Bortezomib is a proteasome inhibitor that interferes with how cells break down proteins, ultimately leading cancer cells to die. Several studies have tested adding bortezomib to standard chemotherapy regimens, with some patients showing encouraging responses.^[8]

Early clinical experience with bortezomib has shown mixed results. Some patients who received bortezomib combined with standard chemotherapy achieved complete remissions and lived longer than typically expected with chemotherapy alone. However, the addition of bortezomib also increases treatment-related side effects, particularly nerve damage causing numbness and tingling in hands and feet. Researchers continue studying the optimal way to incorporate bortezomib into treatment regimens, investigating questions such as which patients benefit most and what doses provide the best balance of effectiveness and tolerability.^[10]

Lenalidomide represents another drug borrowed from the myeloma treatment arsenal. This medication, sometimes called an immunomodulatory drug, works through several mechanisms including stimulating the immune system to attack cancer cells, cutting off blood supply to tumors, and directly interfering with cancer cell growth. Clinical trials have tested lenalidomide both as a single agent and combined with chemotherapy for plasmablastic lymphoma. Some patients have responded to lenalidomide treatment, particularly when combined with other drugs, offering hope that this approach might benefit certain individuals.^[8]

The agent daratumumab has generated considerable interest in the plasmablastic lymphoma community. Daratumumab is a monoclonal antibody—a laboratory-created protein that binds to a specific target on cells. In this case, daratumumab targets CD38, a protein that appears on the surface of plasmablastic lymphoma cells. When daratumumab attaches to CD38, it helps the immune system recognize and destroy the cancer cells. Daratumumab has proven highly effective in treating multiple myeloma, leading to trials testing whether it helps patients with plasmablastic lymphoma.^[8]

Early reports of daratumumab use in plasmablastic lymphoma patients have shown encouraging results. Some patients whose cancer had stopped responding to chemotherapy experienced tumor shrinkage when treated with daratumumab, either alone or combined with other agents. The drug’s ability to harness the patient’s own immune system to fight cancer cells represents an attractive approach, particularly for a disease that often develops in people with compromised immune systems. Clinical trials continue exploring the best ways to use daratumumab, including optimal timing, dosing schedules, and combination partners.^[8]

Another strategy under investigation involves drugs that block immune checkpoints. The immune system has built-in “brakes” called checkpoints that prevent it from attacking the body’s own tissues too aggressively. Some cancers exploit these checkpoints, essentially putting the brakes on immune responses that would otherwise destroy cancer cells. Checkpoint inhibitors like pembrolizumab and nivolumab block proteins called PD-1 and PD-L1, releasing those brakes and allowing the immune system to attack cancer cells more effectively. These drugs have revolutionized treatment for several cancer types, and trials are testing whether they help in plasmablastic lymphoma.^[8]

Selinexor is a drug that works through a novel mechanism by blocking a protein called XPO1. This protein normally helps transport certain molecules out of the cell nucleus. When XPO1 is blocked, tumor suppressor proteins accumulate inside the nucleus where they can properly function to stop cancer cell growth. Early studies testing selinexor in patients with relapsed or refractory plasmablastic lymphoma have shown that some patients respond to this treatment, though side effects including nausea, fatigue, and low blood counts can be challenging.^[8]

Brentuximab vedotin is another antibody-drug conjugate being investigated. This medication combines an antibody that targets CD30, a protein that appears on some plasmablastic lymphoma cells, with a powerful chemotherapy agent. The antibody acts like a guided missile, delivering the chemotherapy directly to cancer cells while sparing healthy cells. Patients whose lymphoma cells express CD30 may benefit from this targeted approach. Research continues into identifying which patients are most likely to respond and how to optimally use this agent.^[8]

Thalidomide, a drug with a controversial history, has shown promise in at least one documented case. A patient treated with thalidomide combined with dexamethasone (a steroid) followed by double autologous stem cell transplantation achieved long-lasting complete remission. This myeloma-inspired approach recognizes the plasma cell characteristics of plasmablastic lymphoma. While this represents just one case report, it suggests that myeloma treatment strategies warrant further investigation in properly designed clinical trials.^[16]

Gene-based therapies represent another frontier under exploration, though still in early stages for plasmablastic lymphoma. Researchers have identified that many plasmablastic lymphomas harbor a genetic abnormality involving a gene called MYC. This gene, when overactive, drives cells to grow and divide uncontrollably. Drugs targeting MYC or the pathways it controls might offer new treatment options. Additionally, understanding the genetic makeup of individual tumors may help identify which patients will respond best to specific therapies, moving toward personalized medicine approaches.^[4]

Clinical trials are being conducted at specialized cancer centers in the United States, Europe, and other regions around the world. Because plasmablastic lymphoma is rare, many trials include multiple subtypes of aggressive lymphomas rather than focusing exclusively on plasmablastic lymphoma. Patient eligibility typically depends on factors including previous treatments received, overall health status, organ function, and specific characteristics of the cancer. Many trials require that patients have disease that has returned after treatment or did not respond to standard therapy, though some trials accept newly diagnosed patients.^[8]

Most Common Treatment Methods

• Standard chemotherapy regimens
  • CHOP chemotherapy combining cyclophosphamide, doxorubicin, vincristine, and prednisone given every 2-3 weeks^[10]
  • DA-EPOCH using dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin delivered continuously^[8]
  • Treatment typically involves 4-6 cycles depending on disease response^[8]
• Stem cell transplantation
  • Autologous stem cell transplantation for patients achieving complete remission after initial chemotherapy^[8]
  • High-dose chemotherapy followed by return of patient’s own stem cells to restore bone marrow^[8]
  • Used as consolidation to reduce risk of cancer returning^[8]
• Targeted antibody therapies
  • Daratumumab targeting CD38 protein on cancer cell surfaces^[8]
  • Brentuximab vedotin for tumors expressing CD30^[8]
  • Used primarily in clinical trials or for relapsed disease^[8]
• Drugs borrowed from myeloma treatment
  • Bortezomib, a proteasome inhibitor, added to chemotherapy regimens^[8]
  • Lenalidomide as an immunomodulatory agent^[8]
  • Thalidomide combined with dexamethasone in selected cases^[16]
• Immunotherapy approaches
  • Checkpoint inhibitors blocking PD-1 or PD-L1 proteins^[8]
  • Medications designed to help the immune system recognize and attack cancer cells^[8]
  • Currently being tested in clinical trials^[8]
• Radiation therapy
  • Used for consolidation after chemotherapy in limited-stage disease^[8]
  • Provides symptom relief for painful or bleeding tumors^[8]
  • Delivered in daily sessions over several weeks^[8]
• Supportive care
  • Antiretroviral therapy continued throughout treatment for HIV-positive patients^[8]
  • Medications to prevent central nervous system involvement in high-risk cases^[8]
  • Palliative care for patients with refractory disease^[8]

Looking Forward: Prognosis and Emerging Research

Despite advances in treatment, plasmablastic lymphoma remains a challenging disease with outcomes that lag behind many other lymphomas. Recent reports indicate median overall survival ranging from 14 to 57 months, with progression-free survival between 6 and 11 months. These numbers represent medians, meaning half of patients survive longer and half shorter than these timeframes. Several factors influence individual prognosis, including whether patients achieve complete remission with initial treatment, performance status measuring overall health and daily functioning, clinical stage at diagnosis, and results of the International Prognostic Index.^[8]

The presence or absence of Epstein-Barr virus (EBV) in tumor cells appears to affect outcomes, with some studies suggesting that EBV-positive cases may have different responses to treatment than EBV-negative cases. The status of MYC, a gene frequently abnormal in plasmablastic lymphoma, also influences prognosis. Patients whose tumors have MYC rearrangements may face more aggressive disease, though research continues to clarify the precise implications of various genetic findings.^[10]

One subtype of plasmablastic lymphoma, sometimes called plasmablastic lymphoma of the elderly, appears to have a significantly better prognosis than most cases. This variant occurs in older adults who may not have obvious immune system problems, though age-related decline in immune function likely contributes to disease development. Understanding why this subtype behaves differently could provide clues for improving treatment of all plasmablastic lymphomas.^[3]

Ongoing research efforts focus on understanding the molecular mechanisms that drive plasmablastic lymphoma, identifying new drug targets, and determining which treatment combinations work best. As more is learned about the biology of this rare cancer, opportunities emerge for developing therapies specifically designed to exploit vulnerabilities in plasmablastic lymphoma cells. The rare nature of the disease makes organizing clinical trials challenging, but collaborative efforts among cancer centers worldwide are helping to advance knowledge and improve care.^[4]